Connection

Maria Lopes-Virella to Diabetes Mellitus, Type 1

Back to Details
This is a "connection" page, showing publications Maria Lopes-Virella has written about Diabetes Mellitus, Type 1.
Maria Lopes-Virella
Connection Strength
6.518
Diabetes Mellitus, Type 1
  1. Plasma apoM Levels and Progression to Kidney Dysfunction in Patients With Type 1 Diabetes. Diabetes. 2022 08 01; 71(8):1795-1799.
    View in: PubMed
    Score: 0.579
  2. Immune Complexes and the Risk of CVD in Type 1 Diabetes. Diabetes. 2019 09; 68(9):1853-1860.
    View in: PubMed
    Score: 0.467
  3. Glycosylated sphingolipids and progression to kidney dysfunction in type 1 diabetes. J Clin Lipidol. 2019 May - Jun; 13(3):481-491.e1.
    View in: PubMed
    Score: 0.460
  4. Response to comment on Lopes-Virella et al. Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects. Diabetes care 2013;36:2317-2323. Diabetes Care. 2014 May; 37(5):e108-9.
    View in: PubMed
    Score: 0.322
  5. Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects. Diabetes Care. 2013 Aug; 36(8):2317-23.
    View in: PubMed
    Score: 0.303
  6. Oxidized LDL immune complexes and coronary artery calcification in type 1 diabetes. Atherosclerosis. 2011 Feb; 214(2):462-7.
    View in: PubMed
    Score: 0.257
  7. Levels of oxidized LDL and advanced glycation end products-modified LDL in circulating immune complexes are strongly associated with increased levels of carotid intima-media thickness and its progression in type 1 diabetes. Diabetes. 2011 Feb; 60(2):582-9.
    View in: PubMed
    Score: 0.256
  8. Distribution of IgM and IgG antibodies to oxidized LDL in immune complexes isolated from patients with type 1 diabetes and its relationship with nephropathy. Clin Immunol. 2008 Jun; 127(3):394-400.
    View in: PubMed
    Score: 0.217
  9. Immune complexes containing modified lipoproteins are related to the progression of internal carotid intima-media thickness in patients with type 1 diabetes. Atherosclerosis. 2007 Feb; 190(2):359-69.
    View in: PubMed
    Score: 0.186
  10. Serum urate and cardiovascular events in the DCCT/EDIC study. Sci Rep. 2021 07 09; 11(1):14182.
    View in: PubMed
    Score: 0.135
  11. Longitudinal Plasma Kallikrein Levels and Their Association With the Risk of Cardiovascular Disease Outcomes in Type 1 Diabetes in DCCT/EDIC. Diabetes. 2020 11; 69(11):2440-2445.
    View in: PubMed
    Score: 0.127
  12. Risk Factors for Diabetic Peripheral Neuropathy and Cardiovascular Autonomic Neuropathy in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes. 2020 05; 69(5):1000-1010.
    View in: PubMed
    Score: 0.122
  13. Risk Factors for First and Subsequent CVD Events in Type 1 Diabetes: The DCCT/EDIC Study. Diabetes Care. 2020 04; 43(4):867-874.
    View in: PubMed
    Score: 0.122
  14. Antibodies to oxidized LDL predict coronary artery disease in type 1 diabetes: a nested case-control study from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes. 1999 Jul; 48(7):1454-8.
    View in: PubMed
    Score: 0.117
  15. Serum apolipoproteins and apolipoprotein-defined lipoprotein subclasses: a hypothesis-generating prospective study of cardiovascular events in T1D. J Lipid Res. 2019 08; 60(8):1432-1439.
    View in: PubMed
    Score: 0.117
  16. Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus. Clin Immunol. 1999 Feb; 90(2):165-72.
    View in: PubMed
    Score: 0.114
  17. Late adulthood mortality among African-American and white American people with Type 1 diabetes according to age at diabetes diagnosis. Diabet Med. 2018 06; 35(6):729-736.
    View in: PubMed
    Score: 0.107
  18. Apolipoprotein-defined lipoprotein subclasses, serum apolipoproteins, and carotid intima-media thickness in T1D. J Lipid Res. 2018 05; 59(5):872-883.
    View in: PubMed
    Score: 0.107
  19. Association Between Inflammatory Markers and Progression to Kidney Dysfunction: Examining Different Assessment Windows in Patients With Type 1 Diabetes. Diabetes Care. 2018 01; 41(1):128-135.
    View in: PubMed
    Score: 0.104
  20. Anti-modified LDL antibodies and LDL-containing immune complexes in IDDM patients and healthy controls. Clin Immunol Immunopathol. 1997 Oct; 85(1):73-82.
    View in: PubMed
    Score: 0.104
  21. Increased Plasma Levels of Select Deoxy-ceramide and Ceramide Species are Associated with Increased Odds of Diabetic Neuropathy in Type 1 Diabetes: A Pilot Study. Neuromolecular Med. 2017 Mar; 19(1):46-56.
    View in: PubMed
    Score: 0.095
  22. LDL from patients with well-controlled IDDM is not more susceptible to in vitro oxidation. Diabetes. 1996 Jun; 45(6):762-7.
    View in: PubMed
    Score: 0.094
  23. Associations between intensive diabetes therapy and NMR-determined lipoprotein subclass profiles in type 1 diabetes. J Lipid Res. 2016 Feb; 57(2):310-7.
    View in: PubMed
    Score: 0.091
  24. Plasma Prekallikrein Is Associated With Carotid Intima-Media Thickness in Type 1 Diabetes. Diabetes. 2016 Feb; 65(2):498-502.
    View in: PubMed
    Score: 0.091
  25. Nuclear magnetic resonance-determined lipoprotein subclasses and carotid intima-media thickness in type 1 diabetes. Atherosclerosis. 2016 Jan; 244:93-100.
    View in: PubMed
    Score: 0.091
  26. Isolation, characterization, and metabolism of the glycated and nonglycated subfractions of low-density lipoproteins isolated from type I diabetic patients and nondiabetic subjects. Diabetes. 1995 Sep; 44(9):1093-8.
    View in: PubMed
    Score: 0.090
  27. Longitudinal Association Between Endothelial Dysfunction, Inflammation, and Clotting Biomarkers With Subclinical Atherosclerosis in Type 1 Diabetes: An Evaluation of the DCCT/EDIC Cohort. Diabetes Care. 2015 Jul; 38(7):1281-9.
    View in: PubMed
    Score: 0.087
  28. Plasma total homocysteine and carotid intima-media thickness in type 1 diabetes: a prospective study. Atherosclerosis. 2014 Sep; 236(1):188-195.
    View in: PubMed
    Score: 0.083
  29. Decreased plasma levels of select very long chain ceramide species are associated with the development of nephropathy in type 1 diabetes. Metabolism. 2014 Oct; 63(10):1287-95.
    View in: PubMed
    Score: 0.083
  30. Oxidized LDL and AGE-LDL in circulating immune complexes strongly predict progression of carotid artery IMT in type 1 diabetes. Atherosclerosis. 2013 Dec; 231(2):315-22.
    View in: PubMed
    Score: 0.079
  31. Apolipoprotein-defined lipoproteins and apolipoproteins: associations with abnormal albuminuria in type 1 diabetes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort. J Diabetes Complications. 2013 Sep-Oct; 27(5):447-53.
    View in: PubMed
    Score: 0.077
  32. Metabolism by human endothelial cells of very low density lipoprotein subfractions isolated from type 1 (insulin-dependent) diabetic patients. Diabetologia. 1993 Mar; 36(3):258-64.
    View in: PubMed
    Score: 0.075
  33. Influence of glycemic control on interaction of very-low- and low-density lipoproteins isolated from type I diabetic patients with human monocyte-derived macrophages. Diabetes. 1992 Oct; 41(10):1301-7.
    View in: PubMed
    Score: 0.073
  34. High concentrations of AGE-LDL and oxidized LDL in circulating immune complexes are associated with progression of retinopathy in type 1 diabetes. Diabetes Care. 2012 Jun; 35(6):1333-40.
    View in: PubMed
    Score: 0.071
  35. High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes. Nephrol Dial Transplant. 2012 Apr; 27(4):1416-23.
    View in: PubMed
    Score: 0.068
  36. LDL-containing immune complexes in the DCCT/EDIC cohort: associations with lipoprotein subclasses. J Diabetes Complications. 2011 Mar-Apr; 25(2):73-82.
    View in: PubMed
    Score: 0.062
  37. Genetic variant in the promoter of connective tissue growth factor gene confers susceptibility to nephropathy in type 1 diabetes. J Med Genet. 2010 Jun; 47(6):391-7.
    View in: PubMed
    Score: 0.062
  38. Interaction of very-low-density lipoprotein isolated from type I (insulin-dependent) diabetic subjects with human monocyte-derived macrophages. Metabolism. 1989 Nov; 38(11):1108-14.
    View in: PubMed
    Score: 0.060
  39. Genome-wide association identifies the ABO blood group as a major locus associated with serum levels of soluble E-selectin. Arterioscler Thromb Vasc Biol. 2009 Nov; 29(11):1958-67.
    View in: PubMed
    Score: 0.059
  40. Enhancement of platelet aggregation by low-density lipoproteins from IDDM patients. Diabetes. 1988 Dec; 37(12):1652-7.
    View in: PubMed
    Score: 0.056
  41. Risk factors related to inflammation and endothelial dysfunction in the DCCT/EDIC cohort and their relationship with nephropathy and macrovascular complications. Diabetes Care. 2008 Oct; 31(10):2006-12.
    View in: PubMed
    Score: 0.055
  42. Connective tissue growth factor and susceptibility to renal and vascular disease risk in type 1 diabetes. J Clin Endocrinol Metab. 2008 May; 93(5):1893-900.
    View in: PubMed
    Score: 0.053
  43. Increased methionine sulfoxide content of apoA-I in type 1 diabetes. J Lipid Res. 2008 Apr; 49(4):847-55.
    View in: PubMed
    Score: 0.053
  44. Stimulation of cholesteryl ester synthesis in human monocyte-derived macrophages by low-density lipoproteins from type 1 (insulin-dependent) diabetic patients: the influence of non-enzymatic glycosylation of low-density lipoproteins. Diabetologia. 1987 Dec; 30(12):916-23.
    View in: PubMed
    Score: 0.052
  45. Glycosylation of low density lipoprotein in patients with type 1 (insulin-dependent) diabetes: correlations with other parameters of glycaemic control. Diabetologia. 1986 Oct; 29(10):685-9.
    View in: PubMed
    Score: 0.048
  46. Nuclear magnetic resonance-determined lipoprotein subclass profile in the DCCT/EDIC cohort: associations with carotid intima-media thickness. Diabet Med. 2006 Sep; 23(9):955-66.
    View in: PubMed
    Score: 0.048
  47. Diabetic lipoprotein deficient serum: its effect in low density lipoprotein (LDL) uptake and degradation by fibroblasts. Metabolism. 1985 Dec; 34(12):1079-85.
    View in: PubMed
    Score: 0.046
  48. Novel predictors of overt nephropathy in subjects with type 1 diabetes. A nested case control study from the Pittsburgh Epidemiology of Diabetes Complications cohort. Nephrol Dial Transplant. 2006 Jan; 21(1):93-100.
    View in: PubMed
    Score: 0.045
  49. Markers of endothelial dysfunction in the prediction of coronary artery disease in type 1 diabetes. The Pittsburgh Epidemiology of Diabetes Complications Study. J Diabetes Complications. 2005 Jul-Aug; 19(4):183-93.
    View in: PubMed
    Score: 0.044
  50. The prospective association between adiponectin and coronary artery disease among individuals with type 1 diabetes. The Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia. 2005 Jan; 48(1):41-8.
    View in: PubMed
    Score: 0.043
  51. Proatherogenic and proinflammatory properties of immune complexes prepared with purified human oxLDL antibodies and human oxLDL. Clin Immunol. 2002 Oct; 105(1):81-92.
    View in: PubMed
    Score: 0.037
  52. Surface binding, internalization and degradation by cultured human fibroblasts of low density lipoproteins isolated from type 1 (insulin-dependent) diabetic patients: changes with metabolic control. Diabetologia. 1982 Jun; 22(6):430-6.
    View in: PubMed
    Score: 0.036
  53. Plasma lipids and lipoproteins in young insulin-dependent diabetic patients: relationship with control. Diabetologia. 1981 Sep; 21(3):216-23.
    View in: PubMed
    Score: 0.034
  54. Immunochemical characterization of purified human oxidized low-density lipoprotein antibodies. Clin Immunol. 2000 May; 95(2):135-44.
    View in: PubMed
    Score: 0.031
  55. Platelet function during continuous insulin infusion treatment in insulin-dependent diabetic patients. Diabetes. 1985 Nov; 34(11):1127-33.
    View in: PubMed
    Score: 0.011
  56. Autoimmune response to advanced glycosylation end-products of human LDL. J Lipid Res. 2003 Mar; 44(3):487-93.
    View in: PubMed
    Score: 0.009
  57. Soluble immune complexes in patients with diabetes mellitus: detection and pathological significance. Diabetologia. 1981 Sep; 21(3):184-91.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.